Literature DB >> 9935015

Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty.

J K Mickelson1, M N Ali, N S Kleiman, N M Lakkis, T W Chow, B J Hughes, C W Smith.   

Abstract

OBJECTIVES: The purpose of this study was to monitor the effects of chimeric 7E3 Fab (ReoPro) on leukocyte and platelet activation and interaction during coronary angioplasty.
BACKGROUND: Increased expression of CD11b on monocytes and neutrophils promotes their adhesion to endothelial cells, extracellular matrix and smooth muscle cells. Thrombin-activated platelets adhere via P-selectin to monocytes and neutrophils. These cell interactions may affect the outcome of coronary angioplasty.
METHODS: During coronary angioplasty, venous blood was obtained for flow cytometric detection of leukocyte CD11b; platelet CD41a, CD61a and CD62P; the percentage of leukocytes with adherent platelets and the intensity of bound platelet fluorescence.
RESULTS: Leukocyte CD11b expression increased after angioplasty in control patients (neutrophils 171+/-25 to 255+/-31 mean fluorescence intensity [MFI, mean+/-SEM], n=25, p < 0.0001; monocytes 200+/-40 to 248+/-36 MFI, n=17, p < 0.05) and decreased in the patients selected to receive chimeric 7E3 Fab (neutrophils 146+/-30 to 82+/-22 MFI, n=25, p < 0.0001; monocytes 256+/- 53 to 160+/-38 MFI, n= 17, p < 0.05). Neutrophil CD11b decreased after in vitro incubation of whole blood with chimeric 7E3 Fab (n=5, p=0.01), but fMLP-induced increases in CD11b were not prevented. The CD11b expression was unchanged and increased with fMLP stimulation after in vitro incubation of isolated neutrophils with chimeric 7E3 Fab. Direct-labeled chimeric 7E3 Fab was not detected bound to neutrophils in whole blood or isolated cells using flow cytometric techniques. Adhesion of isolated neutrophils to protein-coated glass was not prevented by in vitro incubation with chimeric 7E3 Fab. Platelet activation increased after angioplasty in control patients (CD62P 8.9+/-0.8 to 12.3+/-1.2 MFI, n=25, p < 0.05; CD41a 382+/-25 to 454+/-26 MFI, n=25, p < 0.05, CD61a 436+/-52 to 529+/-58 MFI, n=11, p < 0.05); it did not increase in the patients selected to receive chimeric 7E3 Fab (CD62P 13.2+/-1.0 to 9.0+/-0.9 MFI, n=25, p < 0.05; CD61a 398+/-32 to 410+/-38 MFI, n=7, p=NS). Leukocytes with adherent platelets tended to increase in the control group of patients and decrease after the procedure in patients selected to receive chimeric 7E3 Fab; individual and procedure-related variability were marked.
CONCLUSIONS: Despite standard aspirin and heparin therapy, leukocyte and platelet activation with platelet adherence to leukocytes occurs after coronary angioplasty. Although chimeric 7E3 Fab does not bind to leukocytes directly, it influences CD11b expression in whole blood. Modulation of platelet and leukocyte activation and interaction by chimeric 7E3 Fab may contribute to an improved outcome after coronary angioplasty.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935015     DOI: 10.1016/s0735-1097(98)00532-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Rationale for intracoronary administration of abciximab.

Authors:  Enrico Romagnoli; Francesco Burzotta; Carlo Trani; Giuseppe G L Biondi-Zoccai; Floriana Giannico; Filippo Crea
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 2.  Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.

Authors:  Tim Ibbotson; Jane K McGavin; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction.

Authors:  Todd J Anderson
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

4.  Evolving coronary stents coated with new bioactive agents.

Authors:  Yunseok Choi
Journal:  Korean Circ J       Date:  2011-05-31       Impact factor: 3.243

5.  The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.

Authors:  Weon Kim; Myung Ho Jeong; Young Joon Hong; Seng Hyun Lee; Woo Seok Park; Ju Han Kim; In Soo Kim; Myung Ja Choi; Young Keun Ahn; Jeong Gwan Cho; Jong Chun Park; Dong Lyun Cho; Hoon Kim; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2004-12       Impact factor: 2.884

Review 6.  A bumpy and winding but right path to domestic drug-eluting coronary stents.

Authors:  Jae Yeong Cho; Youngkeun Ahn; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2013-10       Impact factor: 3.243

7.  Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury.

Authors:  Inwon Park; Mingyo Kim; Kibaek Choe; Eunjoo Song; Howon Seo; Yoonha Hwang; Jinhyo Ahn; Seung-Hyo Lee; Jae Hyuk Lee; You Hwan Jo; Kyuseok Kim; Gou Young Koh; Pilhan Kim
Journal:  Eur Respir J       Date:  2019-03-28       Impact factor: 16.671

8.  Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model.

Authors:  Young Joon Hong; Myung Ho Jeong; Sang Rok Lee; Seo Na Hong; Kye Hun Kim; Hyung Wook Park; Ju Han Kim; Weon Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.